Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Nashville, TN, US. The stock last traded at $3.92, down 0.76% on the session, giving a market capitalisation of $126.6M. On trailing twelve-month figures it carries a trailing P/E of -2.58, a net margin of -2955.6%. Its beta of 1.80 implies it has historically moved more than the broad market.
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Insight Molecular Diagnostics Inc. is most often compared with the following Healthcare names: